The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study

Klaasen, Ruth; Cantaert, Tineke; Wijbrandts, Carla A.; Teitsma, Christine A.; Gerlag, Daniëlle M.; Out, Theo A.; Nooijer, Monique J. de; Baeten, Dominique; Tak, Paul P.

doi:10.1093/rheumatology/ker010

Cited by 57 publications

(32 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of RF was not associated with CDAI remission rates during TCZ treatment, and a similar result was reported in a previous study with TCZ [19]. Conflicting data exist for TNF inhibitor therapy, with some studies suggesting that the status of RF is associated with a clinical response and some studies reporting no such correlation [20][21][22][23][24][25][26]. In the case of abatacept, efficacy was reported to be lower in patients who were RF negative than those who were RF positive [27].…”

Section: Discussionsupporting

confidence: 85%

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study

Ishiguro

Atsumi

Harigai

et al. 2016

Modern Rheumatology

View full text Add to dashboard Cite

Objective: To evaluate effectiveness and safety of tocilizumab (TCZ) in biologic-naive Japanese patients with rheumatoid arthritis (RA) in real-world settings, and to analyze the relationship between disease duration and clinical outcomes. Methods: The FIRST Bio study was a postmarketing surveillance study of intravenous TCZ in biologics-naive patients who had a prior inadequate response or were intolerant to 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD). Effectiveness, safety, and concomitant csDMARD administration were assessed. Results: Of the 839 patients analyzed, 72.3% completed 52 weeks of treatment. The Clinical Disease Activity Index (CDAI) remission rate at week 52 was 36.8%. Contributing factors for CDAI remission were younger age, early disease stage, and no comorbidities. Health Assessment Questionnaire Disability Index 0.5 was achieved in 65.1% of patients, and was significantly associated with disease duration. Discontinuation of concomitant methotrexate (MTX) and glucocorticoids (GCs) was possible in 19.3% and 34.1% of patients, respectively, without decreasing remission rate. The incidence (events/100 patient-years) of serious adverse events was 18.09, the most common being infection. Conclusion: These data validate the importance of TCZ treatment in the early stages of RA in biologic-naive patients to achieve increased effectiveness. The safety profile of TCZ was reconfirmed. Furthermore, TCZ therapy may allow discontinuation of concomitant MTX and GCs without affecting remission.

show abstract

Section: Discussionsupporting

confidence: 85%

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study

Ishiguro

Atsumi

Harigai

et al. 2016

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…Lipsky et al (2000) also reports that MTX associated with infliximab significantly improved clinical benefit and radiographic progression stops. Klaasen et al (2011) demonstrates that therapy with infliximab reduces the levels of RF and ACPA antibodies after 16 weeks of treatment, which was also confirmed in our results for patients with lowest treatment time, 13 months. Other drugs such as adalimumab and etanercept, also known as biologic DMARDs or TNF blockers, and non-biological DMARDs also showed similar effects, with reduced levels of RF and ACPA throughout drug treatment (Atzeni et al, 2006;Fries et al, 1996).…”

Section: Discussionsupporting

confidence: 90%

Study of advanced rheumatoid arthritis

Carvalho

Andrade

Keusseyan

et al. 2014

RBEB

View full text Add to dashboard Cite

Introduction: Rheumatic diseases are considered public health problems affecting millions of people worldwide resulting in high and rising health-care costs. In this work, Fourier Transform Infrared spectroscopy associated to Partial Least Square regression (PLS) analysis was used to diagnose rheumatoid arthritis (RA) from human serum. Methods: The sera of 94 individuals were collected, which included 47 from rheumatic patients and 47 from healthy individuals. The results from PLS analysis were compared to standard clinical trials such as anti-citrullinated peptide antibodies, C-Reactive protein, and Rheumatoid factor. Results: For clinical diagnosis, the anti-citrullinated peptide antibodies of second generation proved to be the most specific to diagnosis rheumatoid arthritis even after long periods of drug therapy. Conclusions: The qualitative PLS analysis has shown higher values of IgM of RA group, but the difference was very small. The RA patients were under medication, which interfered with the IgM concentration.

show abstract

“…Published studies indicate a degree of inconsistency of the effect of seropositivity to RF or ACPA and the likelihood of response to TNF inhibitors,6 7 19 26–28 or interleukin 6 inhibition 29 30. Based on this study, a placebo-controlled approach, contextualising findings within treatment lines and the exploration of covariates that may modify the relationship are key requirements to adequately examine these complex interactions.…”

Section: Discussionmentioning

confidence: 93%

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

et al. 2012

View full text Add to dashboard Cite

show abstract

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study

Cited by 57 publications

References 22 publications

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study

Study of advanced rheumatoid arthritis

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

Contact Info

Product

Resources

About